TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29090526
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control (not specified treatment)
Study: 27636922
Drug: Decimeter wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decimeter wave therapy and halotherapy in addition to basic drug treatment
Study: 26852501
Drug: Basic drug
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic drug therapy
Study: 16258094
Drug: Risk-adapted alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted alternating short-course multiagent systemic and intrathecal chemotherapy, cranial irradiation if indicated, and conventional maintenance therapy.
Study: 16258094
Drug: Risk-adapted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted treatment for group A (early BM relapse).
Study: 16258094
Drug: Risk-adapted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted treatment for group B (late BM relapse).
Study: 16258094
Drug: Risk-adapted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted treatment for group C (isolated extramedullary relapse).
Study: 16258094
Drug: Risk-adapted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted treatment with individual regimens for 24 patients with exceptionally poor prognosis.
Study: 8062153
Drug: Ipriflavone (IP)
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (IP) 600 mg/day
Study: 28120630
Drug: Ropinirole PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole PR 16 mg
Study: 28120630
Drug: Ropinirole PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole PR 8 mg
Study: 25641537
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet (1500 mg/d)
Study: 25641537
Drug: Moderate-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-sodium diet (2300 mg/d)
Study: 26971236
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg
Study: 3355738
Drug: Glycopyrrolate 0.01
Normalized name: glycopyrrolate 0.0156 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.01 mg kg‐1
Study: 3355738
Drug: Atropine 0.02
Normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.02 mg kg‐1
Study: 2334627
Drug: 0.3‐molar sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3‐molar sodium citrate 15 ml (sodium citrate 1.16 g)
Study: 2334627
Drug: effervescent cimetidine‐sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: effervescent cimetidine‐sodium citrate combination (cimetidine 400 mg with sodium citrate 0.9 g)
Study: 1094842
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of caffeine
Study: 25701265
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and nicotine lozenge
Study: 21269578
Drug: Second TNF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second TNF-alpha inhibitor
Study: 16042672
Drug: Pharmacist-led pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led pharmaceutical care programme
Study: 11124747
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro procyanidin treatment
Study: 9609623
Drug: Tamsulosin 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.8 mg/day
Study: 29556416
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W)
Study: 22834968
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg followed by 40 mg every other week for 7 weeks
Study: 24520548
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg)
Study: 11862974
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis solution containing amino acids and bicarbonate
Study: 11862974
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis solution containing glucose and bicarbonate
Study: 31689513
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) as an adjunct to full-mouth scaling (FMS)
Study: 26493094
Drug: Letrozole (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (adjuvant therapy)
Study: 26493094
Drug: Tamoxifen (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (adjuvant therapy)
Study: 22335305
Drug: 24% ethylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% ethylenediamine tetra‐acetic acid gel (EDTA) applied for 45 seconds on smear-covered dentin in U100/EDTA group
Study: 10418696
Drug: Fluoxetine (FLU)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLU)
Study: 10442214
Drug: Topical evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical evening primrose oil in a stable water-in-oil emulsion
Study: 10442214
Drug: Topical evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical evening primrose oil in an amphiphilic emulsion
Study: 375178
Drug: Heparinized fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized fluids (1 unit/ml)
Study: 28067762
Drug: 12% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% carbohydrate solution (CHO)
Study: 23810332
Drug: Sequential chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiation
Study: 1903616
Drug: Pentigetide, 0.5%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentigetide, 0.5%, ophthalmic solution
Study: 1903616
Drug: Cromolyn sodium,
Normalized name: Cromolyn Sodium, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn sodium, 4%, ophthalmic solution
Study: 28735778
Drug: Yoga classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga classes led by a certified instructor twice weekly for 12 weeks, with home practice.
Study: 28735778
Drug: Delayed yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed yoga treatment (control group).
Study: 11233456
Drug: Both sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sertraline and imipramine
Study: 9374947
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once-a-day
Study: 30105416
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen therapy
Study: 27169634
Drug: Probiotic (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011, 8×10^9 CFU daily)
Study: 1887967
Drug: Atropine 1.2
Normalized name: ATROPINE 1.2/NEOSTIGMINE 2.5MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1.2 mg and Neostigmine 2.5 mg
Study: 31586486
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g test rice
Study: 31586486
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g test rice
Study: 31187048
Drug: Icotinib cream
Normalized name: Nicotine
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib cream (0.5%, 1.0%, 2.0%, and 4.0%) applied twice daily for 4 weeks
Study: 31187048
Drug: Icotinib cream
Normalized name: Nicotine
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib cream (2.0% concentration)
Study: 21879340
Drug: Fact sheet
Normalized name: Corticotropin-releasing factor (sheep)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fact sheet describing HPV vaccine as preventing cervical cancer only (n=81)
Study: 21879340
Drug: Fact sheet
Normalized name: Corticotropin-releasing factor (sheep)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fact sheet describing HPV vaccine as preventing both cervical cancer and genital warts (n=78)
Study: 20920820
Drug: r-HGH replacement
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HGH replacement therapy for 6 months
Study: 11314873
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg citalopram
Study: 9678313
Drug: Adverse effects
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse effects of drug trials
Study: 26607361
Drug: Intravenous regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous regadenoson 100 μg (3 doses)
Study: 26607361
Drug: Intravenous regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous regadenoson 200 μg (3 doses)
Study: 22329914
Drug: GSK233705 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK233705 200 µg
Study: 22329914
Drug: GSK233705 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK233705 12.5 µg, 25 µg, 50 µg, 100 µg
Study: 20939213
Drug: PGE2 intracervical
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 intracervical gel 0.5 mg (maximum of 3 doses, every 6 hours)
Study: 20939213
Drug: Vaginal insert
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal insert of PGE2 (single dose for 24 hours)
Study: 18292959
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic prophylaxis with a single 400‐mg dose of norfloxacin
Study: 16104905
Drug: Betamethasone cream
Normalized name: Betamethasone Cream
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone cream 0.1% applied locally to neurovascular bundles (NVBs)
Study: 16104905
Drug: Usual BNS-RRP
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual BNS-RRP with no corticoid cream
Study: 11796177
Drug: captopril 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 37.5 mg
Study: 2178381
Drug: Betaxolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 40 mg once daily
Study: 2178381
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg 4 times daily
Study: 26592732
Drug: IDeg+IAsp (basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg+IAsp (basal insulin degludec once daily and prandial insulin aspart 2-4 times daily)
Study: 24831447
Drug: Baseline VL
Normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline VL <10,000 copies/ml (N = 314)
Study: 18753646
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (6-g bolus followed by 2 g per hour infusion)
Study: 10604408
Drug: Intensification regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification regimen 2 including perioperative hyperfractionated radiotherapy (9.1 Gy), cisplatin (30 mg/m2 per day), surgical resection with intraoperative radiotherapy boost (7.5 Gy), postoperative radiotherapy (40 Gy to primary site and upper neck, 45 Gy to supraclavicular areas), paclitaxel (135 mg/m2 per 24 hours), and cisplatin (100 mg/m2).
Study: 2117846
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with nitrate-free interval
Study: 15857272
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk protein isolate (25 g/day)
Study: 779497
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline and psychotherapy
Study: 518245
Drug: Nonscheduled treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonscheduled treatment control group
Study: 31477643
Drug: Levetiracetam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (20 mg/kg)
Study: 6139529
Drug: Phenobarbitone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (20 mg/kg)
Study: 26040221
Drug: Ranibizumab monotherapy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monotherapy and ranibizumab + laser
Study: 24066704
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 4 months, delivered in 20 individual outpatient sessions.
Study: 24066704
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT).
Study: 21895039
Drug: Rivaroxaban (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (oral, direct Factor Xa inhibitor)
Study: 21895039
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg once daily) in patients with AF with creatinine clearance of 30-49 mL/min
Study: 15106686
Drug: Inferior alveolar
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inferior alveolar block/long buccal infiltration anesthesia
Study: 15106686
Drug: Infiltration/intrapapillary injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration/intrapapillary injection
Study: 31445509
Drug: Preformed pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preformed pediatric zirconia crowns (EZCrowns, Sprig Oral Health Technologies)
Study: 23726291
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800mg once daily for 14 days
Study: 23726291
Drug: Simvastatin (SMV)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (SMV) 80mg administered alone
Study: 9396639
Drug: Enoxaparin-ticlopidine-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin-ticlopidine-aspirin
Study: 9396639
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (ticlopidine, aspirin)
Study: 8450381
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula (3 mg/L)
Study: 3312212
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (Aristocort A)
Study: 3312212
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream carrier
Study: 23857197
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg intravenous midazolam (high dose)
Study: 23857197
Drug: 0.035 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.035 mg/kg intravenous midazolam (low dose)
Study: 3178924
Drug: Midazolam (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (both doses)
Study: 19961264
Drug: Talampanel 50
Normalized name: Talampanel
DrugBank: Talampanel (DB04982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talampanel 50 mg p.o. t.i.d
Study: 18086066
Drug: Bupivacaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (1 mg x kg(‐1)) and pethidine (1 mg x kg(‐1)) in adrenaline 1:200,000
Study: 1451921
Drug: Vivida cream
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vivida cream applied twice daily for 120 days
Study: 6087475
Drug: Tendamistate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tendamistate (100 mg)
Study: 25733640
Drug: Stable parenteral
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable parenteral amino acid supply (n = 7)
Study: 10690150
Drug: droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 2.5 mg i.v. (group 2, n = 60)
Study: 10690150
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg i.v. (group 3, n = 57)
Study: 8920850
Drug: Reconstituted high-density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted high-density lipoprotein (rHDL) infusion at 40 mg/kg for 4 hours before endotoxin challenge (4 ng/kg)
Study: 1864205
Drug: Aspirin 1000
Normalized name: aspirin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1000 mg/day
Study: 26794605
Drug: MTX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX plus hydroxychloroquine plus sulphasalazine plus low dose prednisone (arm 1)
Study: 20236548
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated split virion influenza vaccine (TIV)
Study: 17394970
Drug: Heparin (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition (GPI)
Study: 31383366
Drug: NPH Insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH Insulin
Study: 17653957
Drug: 0.625/2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625/2.5 mg CE/MPA
Study: 16403987
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (200 mg/day) plus Aspirin (300 mg/day)
Study: 11929349
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg/day)
Study: 10077140
Drug: HFA albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA albuterol
Study: 10077140
Drug: CFC albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC albuterol
Study: 10206134
Drug: Acellular pertussis,
Normalized name: Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis, diphtheria, tetanus vaccine combined with Haemophilus influenzae type b (Hib) vaccine (PRP‐T)
Study: 10206134
Drug: Whole-cell pertussis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis, diphtheria, tetanus/PRP‐T vaccine (historical control)
Study: 2347947
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution (control rinse)
Study: 498714
Drug: Amantadine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (all doses)
Study: 30280368
Drug: Total glucosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glucosides of peony (TGP) 600 mg, tid for 24 weeks
Study: 28369553
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg/day
Study: 29474558
Drug: Chemotherapy (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (intravenous pemetrexed 500 mg/m2 or docetaxel 75 mg/m2)
Study: 17559747
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors (sitagliptin, vildagliptin)
Study: 17559747
Drug: Sulphonylureas, glitazones,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylureas, glitazones, basal insulin
Study: 18006208
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg)
Study: 2292696
Drug: Vigabatrin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (up to 3g daily for eight weeks)
Study: 7264612
Drug: Commercial vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial vaccine
Study: 27776843
Drug: FLOT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT group (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, fluorouracil 2600 mg/m2)
Study: 24117862
Drug: Intravenous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous belimumab 200 mg
Study: 16127757
Drug: HCPT as
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCPT as a major component in anticancer drugs once (control II)
Study: 12403023
Drug: Nelfinavir/Zalcitabine/Zidovudine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir/Zalcitabine/Zidovudine combination
Study: 10457880
Drug: Tramadol suppositories
Normalized name: tramadol hydrochloride Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol suppositories 100 mg 6 hourly (qds)
Study: 7847300
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of famotidine (20 mg bolus followed by 1.67 mg/h infusion)
Study: 7847300
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of famotidine (20 mg every 12 h)
Study: 28988646
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenous every 3 weeks
Study: 16461865
Drug: 192 mg
Normalized name: pancreatin 192 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 192 mg of depot naltrexone
Study: 16461865
Drug: 384 mg
Normalized name: Kuvan 500 MG (sapropterin 384 MG) Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 384 mg of depot naltrexone
Study: 15243283
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol 50 microg daily plus nomegestrole acetate 5 mg/day for 12 days per 28-day cycle for 6 months (Group A)